Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.

(Reuters) - Merck & Co posted higher-than-expected quarterly earnings on Thursday on strong sales of its blockbuster cancer treatment Keytruda, but the drugmaker also flagged a second straight quarter ...

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

Merck, a leading science and technology company, today announced recipients of the fifth annual Grant for Multiple Sclerosis Innovation (GMSI) during the 7 th Joint ECTRIMS-ACTRIMS Meeting in ...

Merck (NYSE:MRK) is scheduled to announce Q3 ... out for updates on Winrevair’s commercial uptake, and comments on Keytruda will also be in focus. UBS says, “On 3Q24 results, we are broadly ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

Global recruitment has also started for this trial, with the first patients enrolling in Canada, according to a press release from Merck, the manufacturer of Keytruda, and Moderna, the manufacturer of ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...